Another GLP-1/glucagon receptor dual agonist (SAR425899) was recently evaluated in single-ascending dose and multiple-ascending dose phase 1 trials where it was given once a day over 28 days.133 At the highest maintenance doses tested, there was a reduction of HbA1c by 0.54–0.59% when given to patients who were overweight or had obesity with T2D, and mean WL of 2.4–5.5 kg over the 28 days.133 SAR425899 was generally well tolerated, with treatment-emergent adverse effects of reduced appetite and nausea.133. Here, GCGR is linked to obesity disorder.